Scripps Research Scientists: Compounds Show Significant Promise Against Botulinum Neurotoxins
Using a multifaceted screening approach, Kim Janda, a Scripps Research scientist who led the study, and his colleagues identified the two compounds and tested their efficacy in both cell-based assays and in mice exposed to the toxin. One compound extended survival time by 36 percent (from 484 minutes to 659 minutes) a remarkable achievement considering its simple structure. Moreover, 16 percent of the animals treated with the second molecule survived with no obvious symptoms of botulism. No significant side effects were observed with either molecule.
Janda pointed out that the two compounds showed surprisingly little activity in cellular assays, suggesting that these standard cell-based screening methods may miss promising therapeutic candidates.
"Our study showed no correlation between cellular activity and in vivo efficacy," Janda said, "which is highly unusual. Clearly, cell-based assays do not provide all the necessary information-animal-based studies are still an essential part of the discovery process. These findings validate our multidisciplinary screening approach to identify unrecognized chemical structures as potential treatments."
Original publication: Lisa M. Eubanks, Mark S. Hixon, Tobin J. Dickerson, Wei Jin, Sukwon Hong, Dale L. Boger, Colin M. Clancy, Eric A. Johnson, William H. Tepp, Michael R. Baldwin, Joseph T. Barbieri, Carl J. Malizio, Michael C. Goodenough, Lim Janda; "An In Vitro And In Vivo Disconnect Uncovered Through High Throughput Identification Of Botulinum Neurotoxin A Antagonists"; Proceedings of the National Academy of Sciences. 2007.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.